We will continue to expand our range of purified excipients, offering pharmaceutical companies a dependable partner
Revenue from operations also dropped 8.3 per cent at Rs. 133.5 crore in Q3 FY25
The Alathur facility specializes in the production of Cephalosporin antibiotics
Total Income during Q3 FY25 stood at Rs. 527.37 crore as compared to Rs. 528.77 crore in Q3 FY24
Branded formulation business continues to perform well across domestic and export markets
The company is committed to revolutionizing API development by advancing synthesis and analytical processes that enhance quality and impact lives
EBITDA margins expand to 31.3%
The change is reflective of the company’s evolving vision aimed at further strengthening its global presence and a commitment to providing innovative solutions in the API and CDMO space
The site’s GMP Certification has been successfully renewed
The EIR was issued with an inspection classification of Voluntary Action Indicated (VAI) post the inspection of the facility from September 16 to September 27, 2024
Subscribe To Our Newsletter & Stay Updated
